Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Post-authorization Study to Describe the Safety and Efficacy of Emapalumab for the Treatment of pHLH in Treatment Experienced Chinese Patients

← catalyst calendar

NCT05744063 · results posted

Sponsored by Swedish Orphan Biovitrum (industry) · SOBI.ST — their whole pipeline →.

Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
13actual
Sites
7
Country
China

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2023-02-03actualWhen the study began enrolling
Primary completion2025-02-21actualThe date the last participant is measured for the primary outcome — the readout window
Study completion2025-08-08actualThe whole study's end, after follow-up
First posted2023-02-24actualWhen this record first appeared on the registry
Results posted2026-03-13actualWhen the sponsor posted results to the registry
Record updated2026-03-13actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Primary Hemophagocytic Lymphohistiocytosis

Intervention

  • Drug: Emapalumab-Lzsg 5 MG/ML [Gamifant] — also filed as Gamifant

Primary outcome

what the primary-completion date above is the date OF
Permanent Discontinuation of Study Drug Due to Emapalumab-related Adverse Event
measured Until conditioning for hematopoietic stem cell transplant (HSCT), likely within 6 months from first dose

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2022-06-01 · 885 KB · Prot_000.pdf
Statistical Analysis Planposted 2025-08-06 · 497 KB · SAP_001.pdf

Permalink · SOBI.ST's whole pipeline · Catalyst calendar · Every registered study · What changed